Omeros Q1 net loss $33.0M ($0.53/shr); OMIDRIA royalties $13.8M; preparing FDA dispute resolution

OMEROS CORP

2022-Q1 EPS reported -$0.53

Net loss of $33.0M ($0.53/shr) vs $35.1M ($0.57) in Q1 2021; non-cash items $4.2M.
Royalty revenue of $13.8M from Rayner's OMIDRIA sales ($27.7M, all U.S.); up from $21.1M prior Omeros net sales.
Cash, equivalents, short-term investments $142.2M at March 31, 2022; down $15M from Dec 2021.
FDA denied narsoplimab BLA (TA-TMA); Omeros plans formal dispute resolution within weeks.
Enrollment expected summer 2022 for Phase 1b OMS906 (PNH) and Phase 1 OMS1029 (long-acting MASP-2).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.